 |
|
Endogenous Estradiol in Elderly Individuals
Cognitive and Noncognitive Associations
V. Senanarong, MD;
S. Vannasaeng, MD;
N. Poungvarin, MD;
S. Ploybutr, MSC;
S. Udompunthurak, MSC;
P. Jamjumras, RN;
L. Fairbanks, PhD;
J. L. Cummings, MD
Arch Neurol. 2002;59:385-389.
ABSTRACT
| |
Objective To investigate an association between endogenous estradiol (E2) levels and cognition and behavior in elderly individuals.
Patients We studied 135 community-based men and women aged 52 to 85 years in
urban Bangkok, Thailand; 72 had dementia and 63 did not.
Materials and Methods Dementia was diagnosed using Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, criteria after appropriate
investigations. Blood samples for assay were collected in the morning after
6 hours of fasting. Levels of E2 were measured by radioimmunoassay
(double antibody technique). The Thai version of the Mini-Mental State Examination
was used to assess cognition; the Neuropsychiatric Inventory was used to assess
neuropsychiatric symptoms; and the Functional Assessment Questionnaire was
used to assess instrumental activities of daily living.
Results There was no correlation between age and level of E2 in either
men or women. Individuals with lower estrogen levels had more behavioral disturbances
(men: r = -0.467, n = 45; P = .001; women: r = -0.384, n = 90; P<.001) and worse cognition (men: r = 0.316, n = 45; P = .03; women: r = 0.243, n = 90; P = .02) and function (men: r = -0.417, n = 45; P =
.004; women: r = -0.437, n = 90; P<.001). The threshold level of endogenous E2 in elderly
individuals for the risk of developing dementia was less than 15 pg/mL (<55
pmol/L) in men and less than 1 pg/mL (<4 pmol/L) in women.
Conclusion Lower E2 levels are correlated with poor cognitive, behavioral,
and functional status in older individuals.
INTRODUCTION
ESTROGEN replacement therapy (ERT) has been reported to be associated
with a decreased risk for dementia and better cognitive function in postmenopausal
women. In the Baltimore Longitudinal Study of Aging,1
a sample of 472 postmenopausal or perimenopausal women was followed for 16
years. After adjustment for educational level, investigators found a relative
risk of Alzheimer disease (AD) in estrogen users of 0.46 compared with nonusers.
Paganini-Hill and Henderson2 found that the
risk for AD decreased with longer duration of estrogen use. Results of observational
studies demonstrate that postmenopausal women perform better on name recall3 and immediate and delayed paragraph recall4 but not on clock drawing5
after ERT. Results of randomized controlled trials indicate that estrogen
therapy improved cognitive function in nondemented postmenopausal women6-9 but that
it is not helpful in women with AD.10-12
A recent meta-analysis by Yaffe et al9
concluded that results of observational and clinical trials of ERT and cognitive
function in AD were inconclusive. Three randomized controlled trials10-12 of ERT published
in 2000 all used conjugated equine estrogen, either 0.625 or 1.25 mg. The
sample sizes ranged from 42 to 120 patients with AD and controls, with treatment
duration ranging from 12 weeks to 12 months. None of these studies found improvement
in cognitive measurements or clinical global assessment findings after estrogen
therapy. Vaginal spotting and deep vein thrombosis were observed as adverse
effects in some treated patients. The results of these studies suggest that
ERT benefits women without dementia but not women with AD.
Although there have been several studies assessing cognitive responses
to ERT, few studies have examined the relationship between endogenous estrogen
status and behavioral or cognitive symptoms in either cognitively intact women
or patients with dementia. We conducted a study of the association of endogenous
estradiol (E2) levels with cognitive impairment and noncognitive
symptoms in demented and nondemented elderly individuals. We had access to
a population of women in Bangkok, Thailand, where the rate of ERT use among
postmenopausal women is low.
PARTICIPANTS, MATERIALS, AND METHODS
The review board of the National Research Council of Thailand and an
ethical committee at the Faculty of Medicine, Siriraj Hospital, Mahidol University,
Bangkok, Thailand, approved this study.
This study was part of a multidisciplinary project studying health promotion
in the elderly conducted by the Faculty of Medicine, Siriraj Hospital (1997-2000).
A door-to-door survey of the community-dwelling elderly population within
10 km of Siriraj Hospital was conducted in 1997. Their names were recorded
and they were included in our ongoing study in the Integrated Health Research
Program for the Elderly at the Faculty of Medicine, Siriraj Hospital. A total
of 3518 elderly individuals from 3 amphurs (city regions) agreed to participate
in the study of mental and nervous systems. The mean ± SD age of this
group was 68.8 ± 7.2 years, and the full range of the Thai Mental State
Examination (TMSE) was represented in participants from this initial survey.
Of the 135 men and women aged 52 to 85 years solicited from this community-based
cohort, 72 had dementia and 63 did not. Internists or neurologists obtained
the medical histories and conducted physical examinations. Dementia was diagnosed
using Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, criteria.13 Exclusion
criteria were delirium and a history of psychiatric disorders before the onset
of memory problems. Blood tests and computed tomography were performed for
individuals with suspected dementia. Alzheimer disease was diagnosed according
to the criteria of the joint task force of the National Institute of the Neurological
and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders
Association.14
Data were obtained via structured questionnaires administered by professional
nurses. The TMSE,15 a translated and culturally
modified version of the Mini-Mental State Examination16
for the Thai population, was used to assess cognitive function. The Neuropsychiatric
Inventory (NPI)17 was applied to caregivers,
relatives, or proxies of the elderly individuals to assess neuropsychiatric
symptoms. The Functional Assessment Questionnaire18
was used to assess activities of daily living. These measures were translated
from English into Thai and then back into English, and any discrepancies were
resolved.
After 6 hours of fasting, 10-mL blood samples were collected from participants
via venipuncture between 7 and 11 AM. Samples were immediately centrifuged,
and the serum was stored at –20°C. Analysis of samples was conducted
within 3 months of blood being drawn. Levels of E2 were measured
by radioimmunoassay (double antibody technique) using a commercial kit (Double
Antibody Estradiol; Diagnostic Products Corp, Los Angeles, Calif).
Statistical analysis was performed using a software program (SPSS 9.0;
SPSS Inc, Chicago, Ill). The  2 test and analysis of variance
were used to test for heterogeneity. Spearman correlation coefficients were
used to assess correlations among measures.
RESULTS
The 63 cognitively healthy individuals and the 72 with dementia were
similar in sex distribution and educational level (Table 1). Alzheimer disease was diagnosed in 37 participants with
dementia, who were significantly older than those without dementia (P<.001), and age was used as a covariate in subsequent
analyses. Most patients with non-AD dementias had vascular dementia. Other
elderly individuals with dementia had Parkinson disease with dementia, dementia
with Lewy bodies, normal-pressure hydrocephalus, and neurosyphilis. Mean E2 levels in men and women were markedly different in demented and nondemented
elderly individuals, with men having higher levels than postmenopausal women
in all diagnostic groups (Table 2).
|
|
|
|
Table 1. Characteristics of the Study Population
|
|
|
|
|
|
|
Table 2. Assessments of Study Groups*
|
|
|
Five of the 135 participants had been receiving ERT: 2 did not have
dementia, and 3 did. Four participants had undergone ERT for less than 6 months
and had stopped more than 5 years before blood samples were drawn for E2 analysis. One individual with dementia had taken estrogens for 2 years
and had stopped a few months before this investigation because of vaginal
bleeding.
To investigate the relationships of estrogen status to cognition and
behavior in each sex, we analyzed the association between E2 levels
and TMSE and NPI scores in men and women. There was no correlation between
age and levels of E2 in either men or women. There was a negative
correlation between total NPI scores and E2 levels in both groups
(men: r = -0.467, n = 45; P = .001; women: r = -0.384, n = 90; P<.001). Patients with lower E2 levels had
higher NPI scores and more marked neuropsychiatric symptoms. In this sample,
relationships between E2 levels and NPI subscale scores did not
reach statistical significance.
There was a positive correlation between global cognitive function as
measured by the TMSE and E2 levels in both groups (men: r = 0.316, n = 45; P = .03; women: r = 0.243, n = 90; P = .02). Lower E2 levels were associated with worse cognition. There were negative correlations
between Functional Assessment Questionnaire scores and levels of E2
in men and women (men: r = -0.417, n = 45; P = .004; women: r = -0.437,
n = 90; P<.001), indicating that individuals with
lower serum E2 levels had greater functional deficits.
The study groups had similar educational levels but differed significantly
in mean age (P<.001). We generated partial correlation
coefficients controlling for age and found that the significant relationships
remained between endogenous E2 levels and TMSE scores (r = 0.187, n = 131; P = .03), endogenous E2 levels and NPI measurement (r = -0.194, n = 131; P = .03), and endogenous E2 levels and Functional Assessment
Questionnaire scores (r = -0.269, n = 131; P = .002).
We analyzed the associations among all 135 samples and found statistically
significant correlations between E2 levels and TMSE scores (r = 0.304, n = 135; P<.001)
and between E2 levels and NPI scores (r = -0.333, n = 135; P<.001). Associations between E2 levels and
TMSE scores were not statistically significant after controlling for NPI scores
(P = .18); similarly, associations between E2 levels and NPI scores were not statistically significant after controlling
for TMSE scores (P = .15). This indicates that low
E2 levels are jointly associated with poor cognitive function and
more severe neuropsychiatric symptoms.
When the relationships of E2 levels to cognitive and behavioral
measures were investigated in the control group and the dementia group individually,
we found no association between endogenous E2 levels and NPI scores
or between endogenous E2 and TMSE scores. The mean ± SD
endogenous E2 level of the nondemented group was 12 ± 13
pg/mL (44 ± 48 pmol/L), and that of the group with dementia was 4 ±
7 pg/mL (15 ± 26 pmol/L). Most participants had serum E2
levels less than 15 pg/mL (<55 pmol/L); this markedly skewed deviation
likely explains the lack of discoverable associations among cognition, neuropsychiatric
symptoms, and E2 levels. However, E2 seemed to reduce
the risk for developing neuropsychiatric symptoms: in these data, individuals
with high NPI scores were more likely to have low E2 levels.
We hypothesized that there was a threshold risk of endogenous E2 levels in elderly persons for developing dementia. Estradiol levels
less than 15 pg/mL (<55 pmol/L) in men and less than 1 pg/mL (<4 pmol/L)
in women carried a relative risk for dementia of 10.83 and 6.23, respectively
(Table 3).
|
|
|
|
Table 3. Threshold Risks of Serum Estradiol Level for Developing Dementia
|
|
|
COMMENT
We demonstrated that elderly individuals with lower E2 levels
have more impaired cognition, more severe neuropsychiatric symptoms, and more
compromised activities of daily living. Previous epidemiologic studies1-2,19-21
found a lower estimated relative risk for developing AD of 30% to 60% in postmenopausal
estrogen users. However, recent randomized trials of women with AD and estrogen
treatment10-12
showed no significant difference in outcomes of cognitive and global assessments
between treatment and placebo groups. These apparently conflicting results
suggest that optimal levels of E2 are needed to maintain brain
function but that ERT may not have therapeutic value once AD is present. Few
studies have assessed the relationship between the level of endogenous E2 and cognition. Our study demonstrates a relationship between cognitive
status, as measured by the TMSE, and endogenous E2 levels, suggesting
that even in individuals with normal cognition, lower E2 levels
are associated with worse cognition.
The data also suggest a risk threshold of endogenous E2 levels
for occurrence of dementia. Levels of endogenous E2associated with
a high risk for dementia were different in women and men, perhaps because
older men have higher levels of testosterone to be converted to E2.
Our results vary somewhat from those of a study by Manly et al,22
who found that the risk for AD was increased 4-fold for E2 levels
less than 20 pg/mL (<73 pmol/L). Yaffe et al23
found an association between higher serum endogenous estrone levels and lower
scores on digit symbol and Trail-Making B tests in 532 women 65 years or older,
and they hypothesized an antagonist effect of estrone to E2.
We found a negative correlation between neuropsychiatric symptoms, as
shown by NPI scores, and E2 levels. A relationship between estrogen
deficiency and increased risk of developing depressive symptoms is supported
by many observational studies. Sherwin24 found
that mood covaried with circulating levels of E2 in surgically
menopausal women. Carlson et al25 also found
a negative relationship between mood scores, as measured by the Geriatric
Depression Scale, and endogenous E2 levels in elderly men and women.
Palinkas and Barrett-Connor26 conducted a cross-sectional
study of 1190 women in California. Mean scores on the Beck Depression Inventory
increased with age in non–estrogen users, whereas no statistically significant
increase in mean scores was found in estrogen users. The NPI used in the present
study measures a variety of neuropsychiatric symptoms, including delusions,
hallucinations, agitation, depression, anxiety, euphoria, apathy, disinhibition,
irritability, and aberrant motor activity. In this sample size, we did not
have sufficient power to identify correlations between NPI subscale scores
and E2 levels.
The association between activities of daily living and E2
levels found in this study may be attributed to the effect of cognitive status
on function. Galasko et al27 found in their
3-year follow-up study that patients with AD who deteriorated faster in functional
activities had more rapid decline in cognitive performance. Other studies28 also demonstrated that dementia severity, measured
by the Mini-Mental State Examination, was a good predictor of everyday functioning.
Estrogen has many plausible benefits for the brain. There are 2 estrogen
receptors,  and ß, which are distributed in different tissues.29 The estrogen receptor alpha is predominantly distributed
in the breast and endometrium, and the estrogen receptor beta is distributed
in the brain, blood vessels, and bone. This may explain the diverse responses
of women to estrogen deprivation and the wide range of adverse effects of
ERT. Certain brain regions, including the amygdala, hippocampus, cingulate
gyrus, locus coeruleus, and basal forebrain, have high levels of estrogen
and progestin receptors.30 Estrogen increases
the number of dendritic spines and synapses in the hypothalamus and cortical
neurons.31 Estrogen stimulates basal forebrain
cholinergic neurons through effects on neurotrophins, nerve growth factor,
and brain-derived neurotrophic factor.32-33
Estrogen promotes vasodilation by inhibiting endothelin and by stimulating
endothelial-derived relaxing factor.34-35
Estrogen promotes production of amyloid precursor protein36
and may reduce deposition of ß-amyloid.37
Estradiol has biological effects on regulation of mood and behavior through
serotonin, norepinephrine, and dopamine.38
The advantage of this study was the availability of groups of elderly
persons with and without dementia of similar educational level and sex distribution.
Few of the women included received ERT. There were only 5 women who had ever
used estrogen. Four of these women had used estrogen briefly and stopped more
than 5 years before the study. The other user was a woman with dementia who
discontinued ERT a few months before the study. The study was cross-sectional,
and some analyses were limited by sample size restrictions. The study depended
on volunteers from a randomized community-based sample, and volunteer status
may have affected the ratio of demented to nondemented individuals in the
study. Volunteer status is unlikely to have been affected by E2levels
or related analyses. Individuals with purely endogenous E2 provide
insight into the relationship between cognitive and noncognitive phenomena
and estrogen. The results add to the emerging data set supporting the hypothesis
that estrogen has beneficial effects on cognition, behavior, and function
in elderly women.
AUTHOR INFORMATION
Accepted for publication August 17, 2001.
All authors take equal responsibility for the design, data acquisition
and interpretation, and statistical measurements of this article.
This study was supported by a grant from the National Research Council
of Thailand for the 1997-1998 fiscal years (Drs Senanarong and Vannasaeng,
and Ms Jamjumras).
Corresponding author and reprints: Jeffrey L. Cummings, MD, Reed
Neurological Research Center, Department of Neurology, UCLA School of Medicine,
710 Westwood Plaza, Los Angeles, CA 90095-1769 (e-mail: cummings{at}ucla.edu).
From the Division of Neurology, Department of Medicine (Drs Senanarong
and Poungvarin and Ms Jamjumras), the Division of Endocrinology, Department
of Medicine (Dr Vannasaeng and Ms Ploybutr), and the Division of Clinical
Epidemiology, Department of Research Development (Mr Udompunthurak), Faculty
of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand; and
the Departments of Psychiatry and Biobehavioral Sciences (Drs Fairbanks and
Cummings) and Neurology (Dr Cummings), University of California, Los Angeles,
UCLA School of Medicine.
REFERENCES
| |
1. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of
developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology. 1997;48:1517-1522.
ABSTRACT
2. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol. 1994;140:256-261.
FREE FULL TEXT
3. Robinson D, Friedman L, Marcus R, et al. Estrogen replacement therapy and memory in older women. J Am Geriatr Soc. 1994;42:919-922.
ISI
| PUBMED
4. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet Gynecol. 1994;83:979-983.
ISI
| PUBMED
5. Paganini-Hill A, Henderson VW. The effects of hormone replacement therapy, lipoprotein cholesterol
levels, and other factors on a clock drawing task in older women. J Am Geriatr Soc. 1996;44:818-822.
ISI
| PUBMED
6. Feddor-Freybergh P. The influence of oestrogen on the well being and mental performance
in climacteric and postmenopausal women. Acta Obstet Gynecol Scand Suppl. 1997;64:1-91.
7. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning
in surgically menopausal women. Psychoneuroendocrinology. 1988;13:345-357.
FULL TEXT
|
ISI
| PUBMED
8. Phillips SM, Sherwin BB. Effects of estrogen on memory function in surgically menopausal women. Psychoneuroendocrinology. 1992;17:485-495.
FULL TEXT
|
ISI
| PUBMED
9. Yaffe K, Sawaya G, Leiberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function
and dementia. JAMA. 1998;279:688-695.
FREE FULL TEXT
10. Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in
AD: a controlled study. Neurology. 2000;54:2061-2066.
FREE FULL TEXT
11. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind,
placebo-controlled trial. Neurology. 2000;54:295-301.
FREE FULL TEXT
12. Mulnard R, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's
disease: a 1-year randomized controlled trial. JAMA. 2000;283:1007-1015.
FREE FULL TEXT
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
14. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA
Work Group under the auspices of the Department of Health and Human Services
Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
FREE FULL TEXT
15. Thai Mental State Examination: Train the Brain Forum Committee (Thailand). Siriraj Hosp Gaz. 1993;45:359-374.
16. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state
of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
FULL TEXT
|
ISI
| PUBMED
17. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology
in dementia. Neurology. 1994;44:2308-2314.
FREE FULL TEXT
18. Pfeffer RI, Kurosaki TT, Harrah CH, et al. Measurement of functional activities on elder adults in the community. J Gerontol. 1982;373:323-329.
19. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med. 1996;156:2213-2217.
ABSTRACT
20. Tang MX, Jacobs D, Stern Y, et al. Effects of oestrogen during menopause on risk and age at onset of Alzheimer's
disease. Lancet. 1996;348:429-432.
FULL TEXT
|
ISI
| PUBMED
21. Morrison A, Resnick S, Corrado M, Zonderman A, Kawas C. A prospective study of estrogen replacement therapy and the risk of
developing Alzheimer's disease in the Baltimore Longitudinal Study of Aging
[abstract]. Neurology. 1996;46(suppl 2):A435-A436.
22. Manly JJ, Merchant CA, Jacobs DM, et al. Endogenous estrogen levels and Alzheimer's disease among postmenopausal
women. Neurology. 2000;54:833-837.
FREE FULL TEXT
23. Yaffe K, Grady D, Pressman A, Cummings S. Serum estrone levels, cognitive performance, and risk of cognitive
decline in older community women. J Am Geriatr Soc. 1998;46:816-821.
ISI
| PUBMED
24. Sherwin BB. Affective changes with estrogen and androgen replacement therapy in
surgically menopausal women. J Affect Disord. 1988;14:177-187.
FULL TEXT
|
ISI
| PUBMED
25. Carlson LE, Sherwin BB, Chertkow HM. Relationship between mood and estradiol (E2) levels in Alzheimer's
disease patients. J Gerontol B Psychol Sci Soc Sci. 2000;55:P47-P53.
26. Palinkas L, Barrett-Connor E. Estrogen use and depressive symptoms in postmenopausal women. Obstet Gynecol. 1992;80:30-36.
FREE FULL TEXT
27. Galasko D, Edland SD, Morris JC, Clark C, Mohs R, Koss E. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD),
part XI: clinical milestones in patients with Alzheimer's disease followed
over 3 years. Neurology. 1995;45:1451-1455.
FREE FULL TEXT
28. Hill RD, Backman L, Fratiglioni L. Determinants of functional abilities in dementia. J Am Geriatr Soc. 1995;43:1092-1097.
ISI
| PUBMED
29. Burger HG. The endocrinology of the menopause. Maturitas. 1996;23:129-136.
FULL TEXT
|
ISI
| PUBMED
30. McEwen BS, Alves SE, Bulloch K, Weiland NG. Ovarian steroids and the brain: implications for cognition and aging. Neurology. 1997;48:S8-S15.
31. Brinton RD, Tran J, Proffitt P, et al. 17-ß-Estradiol enhances the outgrowth and survival of neocortical
neurons in culture. Neurochem Res. 1997;22:1339-1351.
FULL TEXT
|
ISI
| PUBMED
32. Singh M, Meyer EM, Simpkins JW. The effect of ovarectomy and estradiol replacement on brain-derived
neurotrophic factor messenger ribonucleic acid expression on cortical and
hippocampal brain regions of female Sprague-Dawley rats. Endocrinology. 1995;136:2320-2324.
ABSTRACT
33. Toran-Allerand CD, Miranda RC, Benthan WDL, et al. Estrogen receptors colocalize with low-affinity nerve growth factor
receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci U S A. 1992;89:4668-4672.
FREE FULL TEXT
34. Polderman KH, Coen D, Stehouwer A, et al. Influence of sex hormones on plasma endothelin levels. Ann Intern Med. 1993;118:429-432.
FREE FULL TEXT
35. Van Buren G, Yang D, Clark KE. Estrogen-induced uterine vasodilation is antagonized by L-nitroarginine
methylester, an inhibitor of nitric oxide. Am J Obstet Gynecol. 1992;167:828-833.
ISI
| PUBMED
36. Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE. Estrogen regulates metabolism of Alzheimer amyloid ß precursor
protein. J Biol Chem. 1994;269:13065-13068.
FREE FULL TEXT
37. Petanceska SS, Nagy V, Frail D, Gandy S. Ovariectomy and 17ß-estradiol modulate the levels of Alzheimer's
amyloid ß peptides in brain. Neurology. 2000;54:2212-2217.
FREE FULL TEXT
38. Halbreich U. Role of estrogen in postmenopausal depression. Neurology. 1997;48(suppl 7):S16-S20.
RELATED ARTICLE
Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2002;59(3):492-494.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Association of sex steroid hormones with brain morphology and cognition in healthy elderly men
Lessov-Schlaggar et al.
Neurology 2005;65:1591-1596.
ABSTRACT
| FULL TEXT
Cholesterol and Cognition: Rationale for the AD Cholesterol-Lowering Treatment Trial and Sex-Related Differences in {beta}-Amyloid Accumulation in the Brains of Spontaneously Hypercholesterolemic Watanabe Rabbits
SPARKS et al.
Ann. N. Y. Acad. Sci. 2002;977:356-366.
ABSTRACT
| FULL TEXT
More on Hormones and Cognitive Function
JWatch Psychiatry 2002;2002:1-1.
FULL TEXT
|
